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ABSTRACT 
 
The brain can be described as a complex network and its functioning depends on an efficient 
communication between all its components. Large-scale communication is made possible by 
neuronal-network oscillations. Oscillations in the gamma-frequency range (30-80 Hz) are 
associated with cognitive functions such as attention, working memory, sensory perception 
and long-term memory encoding and recall. These oscillations occur in the neocortex and 
hippocampus, and are known to be impaired in many diseases displaying cognitive-deficit 
symptoms, including neurodegenerative diseases. In the studies contained in this thesis we 
investigate basic neuronal mechanisms involved in the generation of gamma oscillations and 
their disruption in models of Alzheimer’s disease and Parkinson’s disease. Moreover, acting 
pharmacologically on different pathways, we try to prevent and/or rescue the impairment of 
the cognition-relevant rhythm and its behavioral consequences. 
In paper I we investigate whether the deleterious effects of amyloid-β peptide on cellular, 
network and behavioral level can be either prevented or rescued by targeted activation of the 
proteasome through the modulation of calcium dynamics. The use of mouse hippocampal 
slices, Drosophila fly models and induced pluripotent stem cells from AD patients showed 
that the inhibition of T-type calcium channels could be an effective therapeutic approach for 
AD and, potentially, other amyloidogenic brain diseases.  
In paper II we study brain hypometabolism and insulin resistance, both known to be risk 
factors for and common outcomes of amyloid-β peptide accumulation. The synergistic use of 
pyruvate, as an alternative source of energy, and insulin, to counteract insulin resistance, is 
efficient in rescuing and preventing synaptic and network dysfunction induced by acute 
application of amyloid-β peptide on mice hippocampal slices.  
In paper III we examine the role of histamine as a potential rhythmogenic neurotransmitter. In 
rat hippocampal slices the perfusion of histamine generates transient dose-dependent gamma 
oscillations, and this action seems to be dependent on the H1 receptor. Our data suggest that 
the generation of gamma oscillations may depend on H1 receptor-mediated inhibition of 
KCNQ channels.  
Lastly, in paper IV we study network activity and behavior of a Parkinson’s disease mouse 
model. The striatal injection of 6-hydroxidopamine disrupts the endogenous circadian rhythm 
of mice, reduces their motor activity and degrades gamma oscillations. Systemic 
administration of a histamine H3 receptor antagonist rescues normal rest/activity cycle and 
memory impairment underlain by gamma oscillations disruption. 
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1 INTRODUCTION 
 
1.1 Overview of the hippocampal formation 
The hippocampus is a complex and fascinating brain region with enormous clinical 
significance. It is a small structure, part of the limbic system, located in the medial temporal 
lobe of the human brain and is of great importance for memory formation, learning, spatial 
navigation and cognition.  
The hippocampus has a distinctive curved shape that has been likened to the sea-horse 
monster of the Greek mythology, hence the name. The hippocampal cortex is composed of 
Dentate Gyrus (DG) and Cornu Ammonis (CA, also known as hippocampus proper), which is 
divided into 3 main regions: CA1, CA2, CA3 (Figure 1). The DG is a structure important for 
episodic memory formation (Nakashiba et al., 2008) and consists mostly of glutamatergic 
granule cells tightly packed to form a granular layer capping the hippocampus proper. It 
receives glutamatergic input from the Entorhinal cortex (EC) through the Perforant Path 
(Figure 1). In turn, cells in the DG give rise to axons (mossy fibers) forming synapses with 
pyramidal cells (PC) in the CA3 region: this region is of particular interest for its role in the 
consolidation of episodic and contextual memories (Nakashiba et al., 2008; Jadhav and 
Frank, 2009). CA3 pyramidal cells send excitatory inputs to the pyramidal neurons in CA1 
through a branch of axons called Schaffer collaterals. Together, these connections form the 
famous trisynaptic excitatory pathway within the hippocampus, described originally by Per 
Andersen (Andersen, 1975). In addition, many CA3 pyramidal cells also have recurrent 
connections. CA1, finally, is the main output of the hippocampus, sending projections back to 
the EC and the subiculum (Amaral et al., 1989), and has high importance in the formation of 
spatial memories (Tsien et al., 1996). CA2 is the least studied among the hippocampal 
regions and it seems to be involved in the formation of social memories (Hitti  & Siegelbaum, 
2014).  
The hippocampus, in addition, receives several subcortical modulatory inputs: from the 
tuberomammillary nucleus (histamine), raphe nuclei (serotonin), locus coeruleus 
(norepinephrine), ventral tegmental area (dopamine) and medial septum (acetylcholine).  
The stratification of the CA area (Figure 1) is largely the same in the different subfields 
(CA1-CA3), with the outermost layer being the alveus, containing solely fibers. The next 
layer is the stratum oriens, containing inhibitory interneurons (IN) and the basal dendrites of 
pyramidal cells. Further inwards we find the stratum pyramidale, containing glutamatergic 
pyramidal cells. The following layer, stratum radiatum, contains inhibitory interneurons and 
associational connections within CA3 and between CA1 and CA3. The innermost layer is the 
stratum lacunosum-moleculare, containing the termination of pyramidal cells apical dendrites 
and axons from the EC. The main difference in the stratification between the different 
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subfields is that CA3 has an additional layer, stratum lucidum, containing the mossy fiber 
axons from the DG, and placed in between stratum pyramidale and stratum radiatum.  
 
 
 
Figure 1. Schematic of the trisynaptic excitatory pathway (a). Axons from layers II (yellow) and III 
(purple) in the Entorhinal Cortex (EC) project to the Dentate Gyrus (DG) through the Perforant Path. DG 
sends projections to CA3 pyramidal cells through mossy fibers. CA3 in turn project to CA1 pyramidal 
cells through Schaffer collaterals. CA1 send projections back to the EC. In b schematic representation of 
the stratification of the CA area: stratum oriens (so) receives afferents from CA3 and contains 
interneurons (red dots); stratum pyramidale (sp) contains the cell bodies of pyramidal cells; stratum 
radiatum (sr) receives afferents from CA3 and contains interneurons (red dots); stratum lacunosum-
moleculare (slm) receives afferents from Entorhinal Cortex. 
 
The hippocampus is thought to be the place where memories are laid down. The relation 
between hippocampus and memory derived from a famous report by Scoville and Milner 
(Scoville et al., 1957): they described the results of surgical removal of the hippocampus in a 
patient named Henry Molaison, in an attempt to relieve him from severe epileptic seizures. 
The outcome of the surgery was an unexpected and severe amnesia. From then on the 
hippocampal formation has been widely studied in its connection to long-term memory. The 
hippocampus, moreover, is the structure where synaptic plasticity was first discovered (Bliss 
& Lømo T, 1973). It has also been extensively studied for its role in spatial memory and 
navigation. O’Keefe and Dostrovsky originally promoted the spatial theory after their 
observations in 1971 (O’Keefe J & Dostrovsky J, 1971), stating that certain cells in the 
hippocampus (“place cells”) are activated when a rat occupies a certain place in the 
environment.  
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1.2 Brain oscillations 
The term “brain oscillations” refers to rhythmic electrical activity generated spontaneously 
and in response to stimuli in the central nervous system (CNS; Basar, 2013). The discovery 
of brain oscillations is credited to Hans Berger, who recorded the first electroencephalogram 
(EEG; Berger, 1929). Many different structures in the CNS are known to be able to generate 
such rhythms. Among these we can find: all cortical areas, cerebellum, olfactory bulb, and 
hippocampus (Gray and Singer, 1989; Hartmann et al., 1998; Beshel et al., 2007; Gray, 
1994). Brain oscillations exhibit a wide range of frequencies (from 0.05 to 500 Hz), and they 
can be grouped in bands within the same neuronal network associated with different brain 
states (Buzsáki and Draguhn, 2004). 
The hippocampus is one of the structures exhibiting some of the most prominent forms of 
synchronous rhythmic activity in the CNS. Hippocampal oscillations have been widely 
studied for their implications in important higher processes in the brain, such as cognition, 
learning, memory and navigation (Winson, 1978; Seager et al., 2002). Oscillations derive 
from synchronous action potential (AP) firing of neurons that give rise to local field 
potentials (LFP) (Börgers and Kopell, 2003; Bartos et al., 2007; Klausberger and Somogyi, 
2008; Atallah and Scanziani, 2009) and they can be divided according to their frequency 
band into delta, theta, beta and gamma. Oscillations in different frequency bands can occur 
simultaneously and, according to their relation, they can represent different behavioral states 
(Gloveli et al., 2010); this coordinated activity seems to play a critical role in memory 
encoding (Lisman, 2005).  
Delta oscillations (0-4 Hz) are associated with slow-wave sleep (Happe et al., 2002; Headley 
and Paré, 2016); theta oscillations (6-10 Hz) are related to locomotor activities defined as 
voluntary, preparatory or exploratory (Vanderwolf, 1969; Buzsáki, 2002); beta oscillations 
(12-30 Hz) are involved in exploration of new environments and movement planning 
(Murthy and Fetz, 1996; Grossberg, 2009). Finally, and most importantly for the scope of this 
thesis, gamma oscillations (30-80 Hz) are fast oscillations associated with cognition, learning, 
memory and attention (Singer, 1993; Buzsáki et al., 2003). Oscillations in the gamma 
frequency band are dependent on precise timing of APs generation and the finely balanced 
interplay between excitatory and inhibitory neurotransmission in the neuronal network 
(Csicsvari et al., 2003; Atallah and Scanziani, 2009; Kurudenkandy et al., 2014). 
Gamma oscillations are disrupted in several brain disorders associated with cognitive decline, 
like epilepsy, depression and schizophrenia (Benedek et al., 2016; Liu et al., 2014; Spencer et 
al., 2008; McNally et al., 2016) and in many neurodegenerative diseases, such as Alzheimer’s 
disease (Goutagny and Krantic, 2013; Kurudenkandy et al., 2014; Nakazono et al., 2018) and 
Parkinson’s disease (Weinberger et al., 2009). 
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1.2.1 Generation of hippocampal gamma oscillations  
Gamma oscillations in the hippocampal formation can be generated either in area CA3 or in 
the DG (Csicsvari et al., 2003). The recurrent excitatory connections in CA3 mentioned 
previously and the perisomatic inhibitory connections (Fisahn et al., 1998) are the perfect 
features allowing this area to sustain its own rhythmic activity without external input.  
Two mechanistic explanations have been proposed for the generation of gamma oscillations: 
Interneuron Network Gamma (ING) and Pyramidal Interneuron Network Gamma (PING).  
The ING model suggests that GABAergic neurons (interneurons) are reciprocally connected 
and that they are sufficient to generate and maintain the rhythmic activity thanks to their 
mutual synaptic inhibition and excitation through gap junctions connections (Hormuzdi et al., 
2001). This is therefore the minimal circuit needed to generate gamma oscillations if 
interneurons are provided with an initial strong and phasic excitatory drive. It is likely, in this 
model, that different classes of interneurons have different involvement in the generation of 
gamma oscillations (Whittington et al., 2000; Figure 2). Pharmacological manipulation of 
metabotropic glutamate receptors in hippocampal slices induced oscillations that persisted in 
absence of excitatory stimuli (Whittington et al., 1995), providing support for the ING model. 
However, ING alone is unlikely to represent a specific model of information processing in the 
CNS, as excitatory cells (i.e. pyramidal cells) are integral part of the cortical network. The 
PING model, on the other hand, proposes that gamma oscillations can only arise from the 
interplay between interneurons and pyramidal cells. In this model pyramidal cells send 
excitatory inputs to interneurons, which in turn inhibit pyramidal cells setting specific time 
windows in which they can fire. According to this model, therefore, the interplay between PC 
and IN is essential to generate and maintain the oscillations (Fisahn et al., 1998; Whittington 
et al., 1997; Atallah and Scanziani, 2009; Buzsáki and Wang, 2012).  
 
Figure 2. Schematic of the interneuron network gamma (ING) and pyramidal interneuron network 
gamma (PING) models. 
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1.2.2 In vitro models of hippocampal gamma oscillations  
Several in vitro models of hippocampal gamma oscillations have been developed to permit 
the study of cellular and synaptic mechanisms in network activity. Alive hippocampal slices 
maintain many aspects of in vivo biology, with preserved architecture and local synaptic 
circuitry, but at the same time they also allow for precise control of the extracellular 
environment (Cho et al., 2007). Hippocampal slices can be used to reproduce gamma 
oscillations using pharmacological or electrical stimulation (Traub et al., 1996) to provide 
excitation to the network. Pharmacologically, they can be induced by activation of 
metabotropic glutamate receptors (Whittington et al., 1995; Gillies et al., 2002), muscarinic 
acetylcholine receptors (Fisahn et al., 1998; Buhl et al., 1998; Hajos et al., 2004) or kainate 
receptor (Buhl et al., 1998; Fisahn et al., 2004). Local gamma oscillations can also be 
classified as transient or persistent. Kainate (KA), by triggering a generalized depolarization, 
and carbachol, by activating the cholinergic system, provide stable and reliable oscillations 
for hours and, therefore, they are useful to explore the mechanisms underlying the physiology 
of oscillations or to modulate them pharmacologically and study the contribution of 
individual neurons. Transient forms of gamma oscillations (lasting for a few seconds or 
minutes at most) can be evoked in vitro by tetanic stimulation (Whittington et al., 1997), 
through pressure ejection of glutamate (Pöschel et al., 2002) or high molarity of potassium 
(LeBeu et al., 2002). Recently, we found a novel and physiological mechanism to induce 
transient gamma oscillations that is described in Paper III in this thesis: the activation of 
histamine receptor H1 elicits transient form of gamma oscillations in area CA3 of rats 
hippocampus, by rendering both PC and fast-spiking interneurons (FS-IN) more excitable.  
The possibility to reproduce gamma oscillations in vitro provides a unique tool that can be 
used to better understand the physiology of the brain and the mechanisms responsible for the 
cognitive decline caused by several brain disorders.  
 
1.3 Neurodegenerative diseases  
Disruption of gamma oscillations has been observed in several neurological conditions and 
neurodegenerative disorders. Such disruption, as said before, is strictly related to the 
cognitive decline associated with neurodegenerative disorders. In addition to neuronal, 
network and cognitive functions decline, many neurodegenerative disorders also manifest the 
hallmarks of protein misfolding and aggregation as well as formation of inclusion bodies. In 
this thesis, the focus lies on Alzheimer’s disease (AD) and Parkinson’s disease (PD).  
 
1.3.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly and affects 
more than 40 million people worldwide. AD is a progressive neurodegenerative disorder, 
which results in the loss of neurons, mainly in the cortex and hippocampus (Nussbaum and 
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Ellis, 2003). It is also a socially disruptive disease, affecting individuals who may live for a 
long time with clinical symptoms and, therefore, represents a socio- and economic- burden. 
This has led to increasing efforts from the scientific community to find therapeutic agents 
able to prevent its progression. Despite this, AD research is still extremely fragmented, with 
no treatment, method of early diagnosis or unifying theory of pathogenesis currently 
available.  
AD is a heterogeneous disorder with both familial and sporadic forms. Sporadic forms are the 
most common, accounting for up to 99% of the cases (Goedert and Spillantini, 2006). 
Familial AD has a very early onset and involves inheritance of a mutated form of Aβ cleaving 
or regulating genes: APP (amyloid precursor protein), PSEN1 (presenilin 1) or PSEN2 
(presenilin 2). AD typically progresses in three general stages: early-stage (mild), middle-
stage (moderate) and late-stage (severe). However, neuronal dysfunction seems to occur a 
decade or more before any clinical sign or symptom of the disease (preclinical stage) and a 
definitive diagnosis can be made only with post-mortem studies. 
Since the first description of the disease by Alois Alzheimer is 1907, it has been clear that the 
neuropathological picture includes aggregates of amyloid-β peptide (now known as amyloid 
plaques) and tangled bundles of fibers of tau peptide (now known as neurofibrillary tangles or 
tau tangles): both amyloid plaques and neurofibrillary tangles are the hallmarks of the 
disease. For the purpose of this thesis, the focus will be on amyloid-β peptide (Aβ).  
The amyloid cascade-hypothesis was originally proposed by Selkoe in 1991 (Selkoe, 1991; 
Hardy and Allsop, 1991) and now dominates AD research. It stipulates that toxic Aβ is one of 
the main culprits for the pathologic neuronal changes in the brain. According to this 
hypothesis the initiating event is the imbalance between the production and the clearance of 
Aβ, resulting in the accumulation of the peptide and leading to neuronal dysfunction, synaptic 
loss and cognitive decline in patients (Hardy and Selkoe, 2002; Walsh and Selkoe, 2007).  
Aβ is produced from its transmembrane precursor, APP, through the sequential cleavage by 
β- and γ-secretase (Haass et al., 1992; Carter and Lippa, 2001; Haass et al., 2012). The γ-
secretase cleavage can bring to two outcomes: most of the Aβ peptides produced are 40 
amino acids long (Aβ40); the less frequent and longer form is Aβ42. This second form is more 
hydrophobic and neurotoxic than Aβ40 and it is the main component of Aβ plaques (Carter 
and Lippa, 2001; LeVine, 2004). The Aβ monomers are soluble and known to aggregate 
extracellularly into oligomers and fibrils (Bucciantini et al., 2002; Crews and Masliah 2010; 
Figure 3).  
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Figure 3. Schematic of the two pathways of APP processing. In the amyloidogenic pathway the β-
secretase cleaves APP releasing sAPPβ and a fragment that is subsequently cleaved by γ-secretase to 
release Aβ40-42. This accumulates, forming oligomers and plaques.  
 
The progressive accumulation of Aβ in the brain (due to excessive production or failure in its 
clearance) initiates many secondary effects, such as insulin resistance (Xie et al., 2002; 
Biessels and Regan, 2015), decreased glucose consumption (Jin et al., 2013), activation of 
microglia and astrocytes (Barger and Harmon 1997; Streit, 2010), neuroinflammation 
(Salminen et al., 2009), dysregulation of calcium homeostasis (Small, 2009; Brawek and 
Garaschuk, 2014), neuron hyperactivity (Busche et al., 2008; Minkeviciene et al., 2009), 
oxidative stress (Cheignon et al., 2018) and synaptic failure (Bayer and Wirths, 2010; Reiners 
et al., 2016; Figure 4).  
 8 
 
 
Figure 4. Schematic of amyloid-β cascade hypothesis. According to this hypothesis, the central event of 
the disease pathogenesis is the imbalance between Aβ production and clearance and many entangled 
downstream effects leading to cognitive decline. ApoE ε4: apolipoprotein E ε4; TREM2: triggering 
receptor expressed on myeloid cells 2; LTP: long-term potentiation. 
 
Among the many Aβ effects, of importance for the scope of this thesis are the dysregulation 
of neuronal calcium homeostasis and hypometabolism. A hypothesis formulated by Chen and 
Nguyen suggests that the combination between energy and calcium signaling deficits is the 
explanation for all the hallmarks of AD (Chen and Nguyen, 2014). 
It is well known that calcium signaling is one of the most important regulatory factors for 
neurons, being involved in many indispensable processes such as synaptic transmission, 
synaptic plasticity and genes transcription. Physiological calcium levels have also been 
proven to promote the non-amyloidogenic pathway in the APP processing (Bezprozvanny 
and Mattson, 2008). However, during normal aging, calcium levels increase in neurons 
(LaFerla, 2002; McInnes, 2013), and it has been long known that the accumulation of Aβ 
results in an abnormal raise of cytosolic calcium in the AD pathology (Mattson et al., 1992; 
Butterfield et al., 1994; Mark et al., 1995). The mechanism through which Aβ initiates the 
calcium influx in neurons has been widely studied (Arispe et al., 1993; Demuro et al., 2005; 
De Felice et al., 2007), but there is still no unifying theory. Actually, it is still debated 
whether the disruption of calcium homeostasis is a cause or a consequence of the disease. In 
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fact, it has also been described that upregulation of calcium levels, in turn, is stimulating the 
production of Aβ (Querfurth and Selkoe, 1994; Pierrot et al., 2006; Ahmad et al., 2009; Itkin 
et al., 2011). Independently of which comes first - Aβ accumulation or calcium dysregulation 
- they create a self-feeding cycle that leads to mitochondria impairment, synaptic signaling 
damage, neuronal apoptosis and, therefore, cognitive decline.  
Another major effect of Aβ accumulation relevant for this thesis is disturbed cerebral glucose 
metabolism accompanied by insulin resistance. The human brain requires great amounts of 
energy, being one of the most metabolically active organs in the body, and its major source of 
energy is ATP derived from glucose. Disturbances in cerebral metabolic rate of glucose in 
AD patients have been described for the first time in 1983 by de Leon (de Leon et al., 1983). 
Since then, research on hypometabolism in AD has bloomed and, similarly to what has been 
said before for calcium, it seems to be both a cause and a consequence of Aβ accumulation 
(Gibson et al., 2010; Simoncini et al., 2014). Hypometabolism seems to start in memory-
related brain regions (Mosconi, 2005) and correlates with cognitive impairment in AD 
patients (Pappatà et al., 2008).  
It is also well known that insulin dynamics play a role in neurotransmission and cognition 
(Rhoads et al., 1984; Kern et al., 2001; Ahmadian et al., 2004; Ghasemi et al., 2013). Insulin 
receptors and insulin-sensitive glucose transporters are present in the brain and they are 
particularly abundant in brain regions involved in learning and memory, such as the 
hippocampus. Insulin resistance seems to promote the expression of APP and the deposition 
of Aβ (de la Monte, 2012) and can exacerbate an already existing AD pathology. Moreover, 
increased Aβ levels give rise to stronger insulin resistance (Xie et al., 2002; De Felice et al., 
2014) creating yet another vicious cycle. However, it seems that insulin does now have a 
significant role in glucose uptake in the brain, and it might play other roles in glucose 
homeostasis (Blázquez et al., 2014).  
 
The original amyloid cascade hypothesis indicated that the main event responsible for all the 
changes in AD brains was the accumulation of insoluble fibrillar Aβ in the extracellular space 
(Selkoe, 1991; Hardy and Allsop, 1991). This hypothesis was later slightly modified and the 
importance of soluble Aβ oligomers was also recognized. Moreover, newer theories suggest 
that intraneuronal Aβ plays an important role in neurotoxicity and in the synaptic pathology 
(Takahashi et al., 2002; Gouras et al., 2010; Mohamed and Posse de Chaves, 2011). One of 
the hypotheses is that Aβ accumulation starts intracellularly, leading to neuronal dysfunction 
(cytosolic disruption and mitochondria failure; Chen and Yan, 2007). This would lead to 
neuronal cell death and the consequent release of Aβ in the extracellular environment 
(Gouras et al., 2000; D’Andrea et al., 2001; Cuello et al., 2005). Another hypothesis is that 
Aβ is taken-up by neurons after its secretion to the extracellular space (Bayer and Wirths, 
2010). There are several theories regarding the mechanism(s) through which the uptake 
occurs: it has been shown that the use of integrin antagonists enhances the Aβ internalization 
and the use of NMDA receptor antagonists blocks it (Bi et al., 2002). It has also been proven 
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that the α7 nicotinic acetylcholine receptor facilitates Aβ uptake (Nagele et al., 2002). 
Moreover, Li and colleagues (2007) suggested that there could be a passive diffusion through 
the membrane. It is clear, however, that both intracellular and extracellular Aβ are important 
in the progression of the disease and they seem to be connected by a dynamic relationship 
(Vetrivel et al., 2005; Crews and Masliah, 2010).  
As mentioned previously, AD is associated with a dramatic decline in cognitive performance, 
which includes also the hippocampus-dependent memory. The main manifestation of the 
alterations of neuronal network patterns in AD patients is the so called “EEG slowing” and 
underlies their cognitive dysfunction (Kowalski et al., 2001). Clinical data show that this 
cognitive decline goes hand-in-hand with a decrease of neuronal network oscillations in the 
gamma frequency band (30-80 Hz; Singer, 1993). It is still debated whether the changes in 
these neuronal rhythms are secondary phenomena in the progression of the disease or a cause 
of the biological and functional changes happening during the progression of the disease. 
Iaccarino and colleagues (2016) have recently proven that optogenetical stimulation of the 
hippocampal region of 5XFAD and APP/PS1 mice (AD models) at gamma frequencies 
reduces Aβ levels. The restoration of gamma oscillations was shown to induce microglial 
morphological changes that promote microglial Aβ uptake. Moreover, through gamma 
stimulation, the processing of APP was altered, inducing a drastic decrease of Aβ generation 
(Iaccarino et al., 2016). Restoration of gamma oscillations is suggested to be a therapeutic 
strategy against Aβ load, even though the underlying mechanisms are yet to be described and 
the translation to human pathologies would still be a challenge.  
Our lab has previously described the mechanisms underlying the degradation of gamma 
oscillations induced by Aβ, finding a desynchronization of AP firing of pyramidal cells and a 
shift in the excitatory/inhibitory currents balance (Kurudenkandy et al., 2014). In paper I and 
II different strategies turned out to be effective in preventing and rescuing those Aβ-induced 
cellular and network changes and, therefore, in restoring the power of gamma oscillations.  
 
1.3.2 Parkinson’s disease 
Parkinson’s disease (PD) is one of the most common age-related neurodegenerative disorders 
affecting 2-3% of the population older than 65 years of age. The first description of the 
disease as a neurological syndrome dates to 1817, when James Parkinson described its 
clinical features in "An Essay on the Shaking Palsy" (Parkinson J, 2002): 
“Involuntary tremulous motion, with lessened muscular power, in parts not in 
action and even when supported; with a propensity to bend the trunk forward, and 
to pass from a walking to a running pace: the senses and intellects being 
uninjured”. 
However, it was Jean-Martin Charcot, 50 years later, who described more in detail the disease 
and named it after Parkinson. In his description in 1872, he pointed out all the major 
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symptoms: resting tremor, bradykinesia, rigidity and the impairment in the ability to initiate 
movements (for review see Goetz, 2011).  
From the first reports of the disease, a lot has been discovered on its pathophysiology, but the 
exact cause of PD is still unknown. For this reason, still only symptomatic treatments exist 
and nothing can be done to halt the neurodegeneration. Although most of the parkinsonian 
cases are sporadic (85-90%) studies on the rare familial cases have given great insight into 
the genetic factors involved in this disease. Many genes have been found to be implicated in 
the familial form of PD (Mhyre et al., 2012). Among these, PARK1/4, SNCA and MAPT 
(Mata et al., 2011) and LRRK2 (Simon-Sanchez et al., 2009) seem to be also involved in the 
sporadic form.  
Even though PD is primarily diagnosed by its motor symptoms, these are preceded by non-
motor symptoms, equally severe and disabling, including olfactory dysfunction, cognitive 
and affective deficits and sleep disorders (Langston, 2006). The disease can impact on 
different cognitive domains, affecting memory, naming, visuomotor and complex attention 
(Hanna-Pladdy et al., 2013). The memory deficits associated with the disease occur more 
frequently in the domains of verbal learning and delayed recall.  
The principal pathological hallmarks of the disease are the progressive loss of dopaminergic 
neurons, starting from the substantia nigra pars compacta (SNpc), and the intracellular α-
synuclein aggregates (called Lewy Bodies; first described by Lewy in 1912). The fact that PD 
patients also experience non-motor symptoms indicates that non-dopaminergic neurons are 
also affected by the disease (Chaudhuri et al., 2006). It seems that pathologic changes precede 
clear outward symptoms by two decades or more (Gazewood et al., 2013): by the time 
symptoms occur, already 60-70% of the neurons in the SNpc have died. The loss of such a 
great amount of these pigmented neurons is the reason why it can be appreciated visually. A 
question that remains open is why the disease affects primarily dopaminergic neurons in the 
SNpc. Dopamine (DA) is involved in complex brain functions including voluntary movement 
and goal-directed behavior, cognition, working memory and wakefulness (Grace et al., 2007; 
Redgrave et al., 2010; D’Ardenne et al., 2012; Arnulf and Leu-Semenescu, 2009). The 
majority of the DA neurons are located in the SNpc as mentioned before, and in the Ventral 
Tegmental Area (VTA). According to their location, DA neurons have different 
electrophysiological properties and a specific gene expression pattern (Roeper, 2013): 
neurons in the SNpc are involved in motor functions while the ones in the VTA support 
cognitive functions (Dragicevic et al., 2015). From the VTA dopaminergic neurons project to, 
among other regions, the hippocampus and the Entorhinal Cortex (Gasbarri et al., 1994). It 
has been seen that there is an association between DA signaling and modulation of gamma 
oscillations (Jay, 2003; Weiss et al., 2003; Andersson et al., 2012a; Andersson et al., 2012b; 
Navakkode et al., 2017). Several studies have shown different effects of DA on hippocampal 
gamma oscillations, depending on the specific receptor involved in the signaling (for review 
see Furth et al., 2013).  
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Although the exact cause of the disease is unknown, several factors seem to contribute to the 
disruption of the DA signaling and to the formation of the Lewy Bodies, such as 
inflammation (Joshi and Singh, 2018), oxidative stress (Hwang, 2013), mitochondrial 
damage (Schapira et al., 1990) and dysfunction of the ubiquitin proteasome system (Dias et 
al., 2013). The presence of α-synuclein aggregates and the absence of dopaminergic activity 
lead, in time, to neuronal death (Figure 5).  
 
 
 
Figure 5: The processing of DA in healthy cells (left) and in the case of Parkinson’s disease (right). In 
PD many different factors contribute to the failure of dopamine metabolism, all together leading to the 
ceasing of post-synaptic signaling and subsequent cell death (Pen and Jensen, 2016). 
 
In the past 40 years PD patients have been treated with Levodopa, a precursor of DA, 
effective in treating symptoms of the disease by compensating for the decreased DA level, 
but bringing many adverse effect, especially motor complications, with long-term use. Other 
treatments involve different DA agonists and, as does Levodopa, come with motor 
drawbacks. Moreover, as mentioned before, these are only symptomatic treatments and 
cannot avoid the progression of the disease. Therefore, new strategies are continuously being 
investigated: fighting the symptoms is not enough and the cause of the disease needs to be 
unraveled and targeted (Pen and Jensen, 2016).   
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2 AIMS 
 
The overall goal of this thesis is to study cognition-relevant network and cellular mechanisms 
disturbed in neurodegenerative disorders, in particular Alzheimer’s and Parkinson’s diseases, 
and explore potential therapeutic avenues to prevent and/or rescue aberrant network rhythms 
and their cellular causes as well as behavioral outcomes. Specific aims for each study are:  
In paper I, investigate whether the deleterious effects of Aβ on cellular, network and 
cognitive features can be prevented or rescued by activation of the proteasome through the 
modulation of cellular calcium concentration/dynamics, achieved by selective inhibition of T-
type calcium channels.  
In paper II, test whether pyruvate and/or insulin can correct AD-typical metabolic 
deficiencies and therefore the downstream network dysfunction in mouse hippocampal slices 
exposed to Aβ, both at cellular and network level.  
In paper III, investigate the role of histamine in promoting gamma oscillations in the 
hippocampus and explore the histamine receptor subtypes and the underlying cellular 
mechanisms responsible for the transient generation of gamma rhythm.  
In paper IV, study the effects of the blockage of H3 receptor on circadian activity, 
recognition memory, anxiety and gamma oscillations in a PD mouse model. 
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3 MATERIALS AND METHODS 
 
This section provides an overview of the methods used in the published articles and 
manuscripts and an explanation on the rationale and motivation behind their use. A detailed 
description of the methods can be found in each article and manuscript.  
 
3.1 Ethical considerations 
All experiments involving animal use were performed in accordance with ethical permits 
issued to Dr. André Fisahn or to Dr. Gilberto Fisone by the regional ethical board in Sweden 
(Norra Stockholms Djurförsöksetiska Nämnd; N45/13 and N114/15). Experiments were 
carefully considered to minimize animal suffering and to reduce the number of animals used.  
 
3.2 Choice of experimental models  
 
3.2.1 Animal Models 
To fill the gap between basic research on neurodegenerative disorders and clinical 
therapeutics, it is essential to have non-human animal models to increase the knowledge on 
the pathophysiology and to assess the efficacy of potential treatments. In non-human species, 
on the other hand, neurodegenerative disorders are an extremely rare condition and 
recapitulating their complexity in terms of clinical feature is still impossible. These diseases, 
in fact, are multifactorial and in most cases animal models are not inclusive of all aspects of 
the disease in question. Animal models have to satisfy several criteria to be considered 
advantageous models: manageable size, relative costs for maintenance, relatively short time 
span, relatively easy genetic manipulation and likelihood to generalize studies to other 
species. Many organisms have been used to mimic parts of different human 
neurodegenerative disorders, including mouse, rats, zebrafish, C. elegans and Drosophila 
melanogaster. Even though each of these species has distinctive advantages for specific 
experimental questions, for the purpose of this thesis the focus will be on rodents and 
Drosophila.  
The mapping of Drosophila’s genome in 2000 unraveled striking sequence homology to 
mammalian genomes (Adams et al., 2000). It has a remarkably short life span and generation 
time, with a very large number of progeny and it is easy to maintain in terms of space and 
resources. All these characteristics facilitate the study of many disorders and, in particular, of 
disorders that manifest late in life, thanks to its short life span. Drosophila also offers unique 
advantages due to its less complicated but well organized CNS: it has neurons and glia, it is 
protected by a blood-brain barrier and the basic cell biology and major neurotransmitters are 
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well conserved (Woodruff-Pak, 2008; McGurk et al., 2015). Moreover, pharmacological 
approaches can be easily used: drugs can be mixed with food, making Drosophila a good 
candidate animal model for screening of therapeutic candidates (Lu and Vogel, 2009).  
As a major part of this thesis work is focused on neuronal network function, the model in use 
was bound to have complex CNS with a neocortex in order to elicit network activity such as 
gamma oscillations. Rodents represent perfect animal models for this scope. Rodents have 
become a key model for the study of neurodegenerative disorders because of their relatively 
short life span and relatively easy genetic manipulation. Rodents are also of great importance 
in research because they can perform learning and memory tasks, rendering possible to 
evaluate cognitive, memory and motor function in health and disease.  
In papers I and II the model used for AD studies is the acute application of amyloid-β to 
hippocampal slices of C57/BL6N male mice (postnatal 14-30). Acute exposure of Aβ1-42 
(from now on Aβ) to hippocampal slices (Kurudenkandy et al., 2014) is a well-established 
method to induce Aβ-related damage to naïve slices and study neuronal network function and 
cells electrophysiological properties. In paper III hippocampal slices from male Sprague-
Dawley rats (postnatal 14-22) were used for local field potential and single cell recordings as 
well as for histology. In paper IV a PD mouse model was used: male C57/BL6N were 
injected with 1 µl of 6-hydroxydopamine (6-OHDA) in each striatum to deplete dopamine 
neurons (first used as a PD model by Ungerstedt, 1968). Control mice received a sham lesion. 
These animals were used for both behavioral experiments and electrophysiology. 
However, these models can recapitulate just part of the complex scenario of each 
neurodegenerative disorder and their genetic manipulation cannot mimic the vast majority of 
cases of neurodegenerative disorders considered in this thesis (AD and PD), which are 
sporadic.  
 
3.2.2 Cell cultures: induced pluripotent stem cells 
Since 2006 when Takahasi and Yamanaka proved that mouse skin fibroblasts can be 
reprogrammed into induced pluripotent stem cells (iPSC; Takahashi and Yamanaka, 2006) 
the scenario for investigation of pathways involved in different diseases and for testing new 
possible therapeutic approaches has changed. Despite the use of animal and human 
embryonic stem cells had and still has a crucial part in drugs screening, it has always been 
accompanied by ethical concerns. However, given the fact that iPSCs are derived from 
somatic tissues of patient, the ethical concerns that have slowed down research with human 
embryonic stem cells have been overcome (Ebert et al., 2012). AD and PD disease models 
from iPSCs have already been developed and are increasingly used as a model for 
investigating disease mechanisms (Kondo et al., 2013) and as a drug screening platform 
(Inoue and Yamanaka, 2011; Yahata et al., 2011). In paper I we characterized 
electrophysiologically iPS cells derived from a patient with familial AD carrying a mutation 
in the APP gene and reprogrammed into neurons.  
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3.3 Electrophysiology 
 
3.3.1 Tissue preparation and maintenance 
For electrophysiological recordings, rodents were anesthetized using isoflurane before being 
sacrificed by decapitation. The brain was dissected and placed in ice-cold artificial 
cerebrospinal fluid (ACSF). Horizontal sections (350 µm thick) of the ventral hippocampi of 
both hemispheres were prepared with a vibratome. After cutting, the slices were transferred 
into a humidified interface holding chamber containing standard ACSF, continuously 
supplied with humidified carbogen gas, and were allowed to recover for at least 1 hour. 
Recordings were then carried out in either interface or submerged chambers (see papers). In 
both cases slices were continuously superfused with ACSF bubbled with carbogen gas, and 
enriched with different compounds depending on the study (see papers).  
 
3.3.2 Local field potential recordings and single-cell experiments 
Local field potential (LFP) recordings were performed in interface or submerged chambers 
according to the nature of the experiments (see papers). Gamma oscillations were induced by 
superfusing KA (100 nM) or carbachol (20 µM) to the extracellular bath. Gamma oscillations 
develop in slices in 3-10 minutes after application and are stable after 20 minutes. Recordings 
at this time point were used as baseline and different compounds were applied after. In other 
cases, application of various compounds was preceding the induction of oscillations 
(prevention vs. rescue strategies, see papers). All recordings were carried on stratum 
pyramidale of hippocampal CA3 area, with ACSF-filled borosilicate glass capillaries pulled 
to a resistance of 3-7 MΩ. Temperature was kept constant throughout the experiment at 34°C 
in order to maintain stable oscillations.  
All single-cell experiments were carried out in a submerged recording chamber. Different 
intracellular solutions were used according to the configuration of the patch-recordings. 
Whole-cell, cell-attached, perforated-patch and single unit configurations were used in 
different experiments (see papers). Concomitant recordings of pyramidal cells firing and LFP 
were carried out to relate each AP discharge to a specific phase of the oscillation.  
 
3.3.3 iPS cells recordings 
Electrophysiological recordings of iPS cells-derived neurons were performed to characterize 
two different cell lines, one derived from a healthy patient (AF22), the other derived from a 
patient with familial Alzheimer’s disease (ADPII), and to test the action of different 
compounds. Cells were plated at a density of 50,000 cells per cm2 on glass coverslips to 
facilitate the passage from the incubator, where they were kept at 37°C with 5% CO2, to the 
submerged chamber, where whole-cell recordings were performed. Passive neuronal 
membrane properties (Resting membrane potential (RMP), input resistance (Rin) and 
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membrane time constant (τ)) were studied to assay their developmental progression over 
time. After characterization of the cell lines in control condition between day 36 and day 75 
of differentiation, cells were used to test compound treatments (see Paper I). 
 
3.4 Behavioral experiments with Drosophila Melanogaster 
Among the many advantages of using Drosophila as animal model, there are its 
standardized behaviors in different scenarios, which can be quantitatively assessed and 
decline with age and/or pathologies.  Flies have the natural tendency to climb as an innate 
escape response. The climbing assay has proven useful in the study of many 
neurodegenerative disorders, including Alzheimer’s disease (Iijima et al., 2004). Flies 
exhibit a negative geotaxis response when given a mechanical stimulus. The principle is to 
place a number of flies in a vial and tap it against a hard surface, strongly enough to cause 
the flies to fall to the bottom of the vial. As a consequence, flies will orient themselves 
rapidly and will attempt to climb to the top of the vial, opposed to gravity (Chakraborty et 
al., 2011; Madabattula et al., 2015). We compared the ability to climb of control and 
experimental flies (overexpressing human Aβ1-42 with Arctic mutation) treated or untreated 
(see details in Paper I) by counting in a set time period how many flies could reach a 
determined line in the vial. Flies were recorded during the task and videos were analysed to 
count flies that could cross the set line. This assay, repeated over time, allows also to 
monitor the progression of the climbing defect, an important feature in the study of 
neurodegenerative disorders.  
 
3.5 Data analysis 
All analysis of electrophysiological experiments was made offline using Clampfit 10.7 
(Molecular Devices, CA), Mini Analysis (Synaptosoft Inc), Axograph X (Berkley, CA), 
Kaleidagraph (Synergy Software), MATLAB (Mathworks, Matick, MA) or IGOR Pro 
(WaveMetrics). Statistical analysis was carried out in GraphPad Prism (GraphPad Software, 
Inc).  
Fast Fourier Transform for power spectra was calculated from 60 seconds long LFP 
recordings using Axograph. Gamma power was calculated as the integrated power spectrum 
between 30 and 80 Hz using Kaleidagraph. In some figures, the data shown are normalized to 
the baseline of KA-induced oscillations, but statistical tests were performed using the raw 
data. In paper I spectrograms were made for visualization purpose using MATLAB but were 
not used for any analysis.  
Synaptic currents were detected offline using Mini Analysis software or custom-made macros 
in IGOR Pro. Charge transfer, amplitude and inter-event-interval (IEI) were analysed using 
GraphPad Prism with the results representing average values taken over 60 seconds periods.  
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Spike phase-coupling analysis was performed on concomitant LFP recordings and single-cell 
recordings using a custom-made routine in MATLAB to relate the pyramidal cells spiking 
activity to ongoing gamma oscillations (Andersson et al., 2012). LFP traces were previously 
filtered in the gamma-band frequencies and APs were detected using an amplitude threshold. 
Using a Hilbert transform, the angle of the oscillation at which each AP occurs can be 
determined. Each AP is represented by a vector of length 1 with an angle corresponding to 
the phase of the oscillation at which the AP occurred. The vectors were then averaged and the 
resultant vector describes the preferred phase of firing (phase-angle) and how recurrent the 
firing in that phase is (vector length).  The peak of the oscillation cycle corresponds to 0 and 
the trough to ±π in the polar plots, with all the phase-angles distributed accordingly.  
Data analysis for iPS cells recordings was performed using Clampfit 10.7. RMP, Rin, τ and 
percentage of cells in which AP occurred were examined. The Rin was calculated from 
voltage-clamp steps recordings and derived from the linear portion of the current-voltage 
plot. All the parameters were analysed using GraphPad Prism. 
All data are represented as mean ± standard error of mean (SEM).  
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4 RESULTS AND DISCUSSION 
 
4.1 Paper I  
Altered calcium homeostasis is one of the consequences of Aβ accumulation in AD. In paper 
I we show that the inhibition of T-type calcium channels has beneficial effects in several 
models of AD and can restore cellular and network function impaired by Aβ, probably 
through the activation of the ubiquitin-proteasome system. 
Disturbance in the protein degradation mechanisms is common in many human diseases such 
as cancer (Devoy et al., 2005; Jara et al., 2013), immunological disorders (Wang and 
Maldonado, 2006) and neurodegenerative diseases (Dantuma and Bott, 2014; Zheng et al., 
2016). The impairment in the ubiquitin-proteasome system (UPS) in AD is well established 
(Keller et al., 2000; Hong 2014) and can be a target for potential therapeutic strategies (Qing 
et al., 2004; Gadhave et al., 2016).  
This study began in collaboration with a biotech company through which we had access to 14 
FDA-approved drugs all sharing the ability to increase proteolysis (Leestemaker et al., 2017). 
One of these drugs, Pimozide, is the object of study in this paper.  
To evaluate Pimozide, we initially tested its effects on a Drosophila Melanogaster model of 
AD, created by Crowther and colleagues as a drug-testing tool (Crowther et al., 2005). The 
aim of these experiments was to understand if this drug could have any functional benefits 
and/or could decrease the burden of Aβ aggregates in a very severe model of the disease in a 
short time. The behavioral test (climbing test) showed a clear improvement of the animals 
treated with Pimozide over sham treated flies. The genetic controls used and treated with the 
drug showed no adverse effects. The reason behind the improvement in the motor ability of 
the treated flies was revealed by immunohistological studies on whole brains stained for Aβ. 
We observed a significant reduction of the size and number of Aβ aggregates in treated flies 
compared to the sham treated ones.  
With these first very encouraging results, we set out to study Pimozide’s effect on a model 
that could give us more insight into the cognitive decline typical of AD. As said previously, 
cognitive decline is strictly related to gamma oscillations disruption in many 
neurodegenerative disorders. Gamma oscillations can be studied both in vivo and in vitro: in 
in vitro studies they represent a useful tool to test effects of compounds on a cognition-
relevant network activity, and they could be a remarkable functional biomarker for diagnosis 
if studied on patients. 
The effect of Aβ on KA-induced gamma oscillations has been widely explored 
(Kurudenkandy et al., 2014) and some results were replicated in this study as controls to the 
compound’s treatment. We performed experiments to evaluate potential preventive effects of 
Pimozide for Aβ-induced degradation of gamma oscillations, and we found that the drug was 
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effective in preventing the degradation in a concentration-dependent manner. With these 
promising preventive results we started wondering what the mechanism behind Pimozide’s 
action could be. Pimozide is known to act on several receptor subtypes as an inhibitor or an 
antagonist. To dissect the mechanism responsible for its actions, we tested several specific 
inhibitors for receptors or channels known to be targeted by Pimozide. The only other 
compound able to reproduce the same effect observed with Pimozide on Aβ-disrupted 
gamma oscillations was the specific T-type calcium channel inhibitor, Penfluridol. This result 
is in accordance with the alterations in the calcium homeostasis in AD that have been studied 
since the ’90s (Mattson et al., 1992, 1993; Arispe et al., 1993) and are known to be a central 
issue in the disease. However the specificity to T-type calcium channels is novel. 
Although the preventive effects of these T-type calcium channel inhibitors are of importance, 
the definition of “preventive” itself renders them less valuable from a clinical perspective. In 
a disease such as AD, in which pathologic changes occur several years before the clinical 
symptoms and there is no effective early-diagnosis tool, a preventive drug would be, 
unfortunately, of little use. We therefore tested the two T-type calcium channel inhibitors 
(Pimozide and Penfluridol) on hippocampal slices previously treated with Aβ to evaluate 
their potential restorative effect on gamma oscillations; we observed a partial rescue over 
time with both compounds and with two additional T-type calcium channel inhibitors with a 
different chemical structure, NNC55-0396 and ML-218.  
Knowing that several cellular and synaptic mechanisms can underlie the changes in gamma 
oscillation power, we proceeded to examine the balance between excitatory and inhibitory 
synaptic activity and the phase-synchronized AP firing (Fisahn et al., 2004; Leão et al., 
2009). First, we studied the synaptic properties of CA3 pyramidal cells. It has been 
previously shown that Aβ changes the equilibrium between excitation and inhibition 
(Kurudenkandy et al., 2014). To test whether T-type calcium channel inhibition could restore 
this balance, we recorded excitatory (EPSCs) and inhibitory (IPSCs) postsynaptic currents in 
slices activated with KA. Both Pimozide and Penfluridol proved to be effective in restoring 
the Aβ-induced increase of EPSCs’ amplitude and frequency to their normal levels, while 
they were ineffective on reduced IPSCs, where the decrease initiated by Aβ continued over 
time even in presence of either of the two inhibitors. This selective effect on synaptic 
properties may be the explanation for the partial rescue of disrupted gamma oscillations seen 
in our previous experiments.  
Secondly, we performed single unit recordings of pyramidal cells concomitant with LFP 
recordings in hippocampal slices activated with KA. The acute application of Aβ resulted in, 
as seen before, a severe reduction of gamma oscillations in concomitance with an increase in 
APs firing frequency of PC. Spike-phase coupling was also evaluated before and after Aβ 
treatment. We found a substantial desynchronization of AP firing in relation to the gamma 
cycle and a shift in the AP preferred phase-angle. After the application of Aβ we applied in 2 
separate sets of experiments Pimozide and Penfluridol. In both cases we found that, in 
addition to the partial gamma oscillations rescue seen before, the AP firing frequency 
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decreased back to normal level. Moreover, analysing the AP spike-phase coupling after 
compound applications we observed that the treatments had completely rescued the 
desynchronization of AP firing and the shift in the AP preferred phase-angle.  
To bring this study a step further toward the complexity of the human disease, we took 
advantage of the relatively new iPS cell technology. These cells can recapitulate diseases in a 
dish and can be extremely useful to test drugs. For this reason we electrophysiologically 
characterized one line of iPS cells derived from a healthy patient (AF22) and one line derived 
from a patient with familial AD (APP mutation, ADPII). We monitored the passive 
membrane properties and firing ability of these two lines for 40 days, between day 35 and day 
75 of differentiation. The comparison of the different parameters of these two lines revealed 
that although during the differentiation process the AD cell line matures faster than the 
control, it also degenerates faster. However, a 48-hour treatment of the ADPII line with 
Penfluridol or Pimozide toward the end of our time frame, when the degeneration was 
already ongoing, turned out to be effective in bringing all the passive membrane properties 
and firing frequency to levels similar to those of the AF22 line. Further basic characterization 
of these cell lines needs to be done and is ongoing. Moreover, further investigation of the 
effects of the two T-type calcium channel inhibitors on this model is necessary since our 
initial results are very encouraging. 
Although calcium has been proven of importance in the activation of the proteasome 
machinery (Djackovic et al., 2009), the excess of calcium influx in the cells due to Aβ is 
deleterious and creates a vicious cycle (LaFerla, 2002). However, there are some 
controversies in the field. Some studies suggest the blockage of calcium channels as a 
therapeutic strategy for AD (for review, Yu et al., 2009), and most of them are focused on the 
L-type calcium channels (Yagami et al., 2004; Anekonda et al., 2011; Paris et al., 2011). The 
selectivity of the available T-type calcium channel blockers and, even more, L-type calcium 
channel blockers doesn’t allow for a definitive distinction between the two. Most of them 
have overlapping effects, with slight preferences toward one of the two channel types. 
Although Pimozide and Penfluridol are not very specific drugs, the use in this paper of the 
more selective and structurally different NNC55-0396 and ML-218 proves the link between 
the gain-of-function we see and T-type calcium channels.  
Overall, this study highlights the importance of the dysregulation of calcium homeostasis in 
relation to the proteasome machinery in AD, and offers a potential avenue toward its 
restoration through the inhibition of T-type calcium channels. 
 
4.2 Paper II 
In this paper we discuss the connection between Aβ and hypometabolism and a potential 
combinational treatment acting on reduced glucose metabolism and insulin resistance.  
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Among the earliest symptoms of AD, hypometabolism has a central role. It manifests as 
changed glucose consumption (Jin et al., 2013), neuronal energy deficit and oxidative stress 
(Gella and Durany, 2009). Glucose metabolism is reduced by ~50% in sporadic AD, while it 
seems to be not so much affected in familial AD (Hoyer, 1992). Hypometabolism itself seems 
to contribute to production and accumulation of Aβ (Velliquette et al., 2005; Koike et al., 
2010), which in turn leads to many downstream effects including insulin resistance (Xie et 
al., 2002; Biessels and Reagan, 2015), further glucose consumption impairment (Carrano et 
al., 2011), hyperactivity of neurons, astrocytes and microglia as well as calcium homeostasis 
dysregulation (Brawek and Garaschuk, 2014).  
We have previously shown that AD-related network hyperexcitability is due to a depolarizing 
effect of Aβ, both in ex-vivo hippocampal slices from transgenic mice (Zilberter et al., 2013) 
and from wild-type hippocampal pyramidal cells during acute Aβ application (Kurudenkandy 
et al., 2014). However, in our recordings from CA3 pyramidal cells in whole-cell 
configuration we did not see any membrane potential depolarization, seen as a lack of 
changes in the holding current at -70 mV. This was surprising and intriguing and made us 
wonder if the reason of this difference could be a technical issue. In fact, the previous results 
were obtained either using completely non-invasive cell-attached recordings or the relatively 
non-invasive perforated-patch configuration. In both cases, the intracellular make-up remains 
unaltered. The intracellular solution used for whole-cell recordings contained 2 mM Na2-
ATP: in this configuration, the recording pipette solution can diffuse inside the recorded cell, 
compensating for a potential lack of energy and preventing the Aβ-induced depolarization. 
Successive experiments with different concentration of ATP in the intracellular solution 
proved that when the external energy source was lowered, the deleterious effect of Aβ 
presented itself again. Moreover, if the ATP concentration was considerably reduced the 
depolarization of the recorded cell occurred even in absence of Aβ. Therefore, we concluded 
that Aβ depolarizes pyramidal cells by inducing an intracellular ATP shortage. This deficit 
can have many effects on all ATP-dependent processes in the neurons: for instance, the 
depolarization of the membrane could be due to the malfunctioning of the Na+/K+ ATPase, 
responsible for the maintenance of the resting membrane potential.  
Another effect of Aβ on neurons is insulin resistance (Xie et al., 2002; Hoyer, 2004; Pearson-
Leary and McNay, 2012). Physiologically, insulin increases glucose uptake into cells (Leney 
and Tavaré, 2009) by inducing the translocation of glucose transporters (GluTs) to the plasma 
membrane. Insulin resistance could therefore bring to a decrease of this translocation with 
consequent glucose metabolism impairment (Pearson-Leary and McNay, 2012; Jin et al., 
2013). With western-blot analysis we checked the levels of the insulin-dependent glucose 
transporter GluT4 and insulin-independent GluT1 and GluT3 in activated hippocampal slices 
(carbachol, 20 µM) from WT mice in control condition and after acute Aβ application. We 
found no changes in membrane expression of any glucose transporters after treatment with 
Aβ. In accordance with our results, other studies have revealed no changes in the expression 
of GluTs in different AD mouse models (Hooijmans et al., 2007; Chen et al., 2014). Also, 
post-mortem brain studies have revealed no changes in the expression of GluT4 in AD 
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patients (Steen et al., 2005) and no changes in glucose uptake by insulin administration 
(Talbot et al., 2012). Together, these results suggest that glucose transport is not involved in 
Aβ toxicity on neuronal energy metabolism. 
The decreased glucose metabolism, with consequent ATP shortage, and the insulin resistance 
induced by accumulation of Aβ have very important role in the pathogenesis of AD. We 
hypothesized that acting on these two processes could stop the vicious cycle of AD 
progression. To counteract energy deficiency we used pyruvate, the principal mitochondrial 
source of energy and potent ROS scavenger; to counteract insulin resistance we used insulin. 
In perforated-patch experiments we observed that the addition of pyruvate to the bath solution 
completely prevented the depolarization of CA3 hippocampal pyramidal cells induced by Aβ. 
Insulin perfusion before Aβ application also prevented the depolarization, though not 
completely.  
As said for Paper I, in presence of Aβ there is a shift in the neuronal network 
excitation/inhibition balance (Kurudenkandy et al., 2014) seen as a decrease in IPSCs 
amplitude and frequency and an increase in EPSCs frequency in activated slices. Presence of 
pyruvate in the bath completely prevented the Aβ-induced frequency increase of EPSCs, 
while it had no effects on the Aβ-induced reduction of IPSCs’ frequency or amplitude. 
Conversely, insulin presence before Aβ application was effective in preventing completely 
the Aβ effects on IPSCs but had only a weak effect on EPSCs. Since it has been reported that 
insulin-like growth factor 1 (IGF-1) receptor signaling regulates differently spontaneous and 
evoked excitatory transmission in hippocampal synapses (Gazit et al., 2016), we studied 
miniature EPSCs (mEPSCs) as well. This revealed a different scenario: insulin had a very 
strong effect on mEPSCs (in line with what reported by Gazit and colleagues (2016)), 
maintaining them at control level in presence of Aβ, while pyruvate had a partial preventive 
effect.  
Moreover, we studied gamma oscillations: we found that the detrimental effect caused by 
acute Aβ application on hippocampal slices is also evident in carbachol-induced gamma 
oscillations. In control conditions, neither insulin nor pyruvate showed any effects on gamma 
oscillations. However, when perfused after Aβ application, they both partially restored the 
disrupted gamma power. The restorative effect of insulin on gamma oscillations was blocked 
by the presence of insulin receptor antagonist, suggesting that insulin’s effect is mediated by 
insulin receptors rather than IGF-1 receptors.  
All these results seem to support the idea that insulin and pyruvate normalize the Aβ effects 
through different pathways. Since these effects are in part non-overlapping, the use of the two 
compounds synergistically could be an effective treatment for the several deleterious effects 
exerted by Aβ. In fact, the application of pyruvate and insulin combined (PIN) on Aβ-
disrupted gamma oscillations completely recovered their power.  
We suggest that acting on the pathways leading to Aβ accumulation might be a good strategy 
in the fight against AD. However, because AD is a disease with many different intricate risk 
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factors and cascade events, the counteraction of any of them alone might not be sufficient. In 
this paper we show that a synergistic compensation of two main damaged pathways is 
effective in restoring cognition-relevant network rhythmicity and the responsible cellular 
parameters.  
 
4.3 Paper III 
In this paper we show that the activation of histamine receptors generates transient gamma 
oscillations in the area CA3 of the hippocampus, in a dose-dependent manner, and that this 
effect is dependent on H1 receptor. 
Apart from the role of histamine in mediating allergic reactions, gastric acid secretion and 
inflammation, histamine also has an important role as a neurotransmitter in the CNS. The 
central histamine system is involved in many brain functions such as wakefulness, arousal, 
control of pituitary hormone secretion, attention and cognitive functions. The histaminergic 
neurons originate from the tuberomamillary nucleus in the dorsal hypothalamus and they 
send projections to many areas of the brain (Garbarg et al., 1974), including pyramidal cells 
in area CA3 and CA2 of the hippocampus (Maglóczky et al., 1994).  
The action of histamine in the brain is mediated by four histamine receptors (H1-H4), all of 
which are G-coupled receptors. H1 and H2 are largely excitatory, being coupled to Gq and Gs 
proteins respectively (Black et al., 1972); H3 and H4, on the other hand, are mostly 
inhibitory, being coupled to Gi/o proteins (Arrang et al., 1983; Nguyen et al., 2001). However, 
H4 receptor is so poorly present in the CNS that its very existence has been debated for a 
long time (Strakhova et al., 2009); its physiological effects, moreover, are still poorly 
understood.  
We started this study by examining the distribution of histamine receptor subtypes in the 
hippocampus of young (18 days postnatal) and adult (6 months old) rats. Since there are no 
available antibodies specific for each histamine receptor subtype, we used in situ 
hybridization probes targeting mRNA of H1, H2, H3 and H4 receptors to study their gene 
expression. We observed that H1, H2 and H3 receptor are highly expressed in various areas 
of the hippocampus, with small differences related to the age of the animal, while H4 
expression could not be detected. Moreover, H1, H2 and H3 were mostly expressed in 
stratum pyramidale of CA3.  
We then confirmed that the application of histamine depolarizes CA3 pyramidal cells, as 
previously reported (Yanovsky and Haas, 1998). In our hands, histamine induced a 
depolarization of the resting membrane potential of pyramidal cells, an increase in their 
membrane resistance and a decrease of the rheobase current (amount of current needed to 
trigger an action potential). It also induced a conspicuous increment of the spontaneous firing 
of PC. Similar results were found on FS-IN, which doubled their action potential firing rate in 
presence of histamine. Because histamine was able to excite both PC and FS-IN we 
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hypothesized that it might have an effect on the network activity as well. In fact, the 
application of histamine on quiescent hippocampal slices resulted in the generation of gamma 
oscillations whose power quickly increased within the first 60 seconds after application, and 
then gradually decreased in a 10 minutes time frame. These transient gamma oscillations 
generated by histamine are dose dependent, and the use of excessively high concentration of 
histamine resulted in PC depolarization block and failure to generate gamma oscillations.  
After having established that histaminergic rhythmogenesis was due to the direct action of 
histamine on CA3 neurons (see paper), we set out to establish through which receptor 
subtype histamine was inducing the generation of gamma oscillations. By blocking each 
histamine receptor with its specific antagonist, we established that H1 receptors are necessary 
to induce network activity in the gamma frequency range, and H3 receptor might be involved 
as regulators of histamine-induced activity. H1 receptors have been reported to inhibit “leak” 
potassium currents (Haas et al., 2008), promoting neurons excitability. Given that the H1 
receptor is coupled to Gq/11, which is known to inhibit one type of potassium channel, KCNQ 
channels (Brown and Passmore, 2009), we decided to investigate the possible role of these 
channels in the histaminergic rhythmogenesis. KCNQ channels are important for the 
maintenance of the resting membrane potential and are expressed in both PC and FS-IN; they 
are slow to activate and deactivate and they do not inactivate. We could therefore study the 
tail currents after depolarization steps. We observed that the application of histamine reduces 
these tail currents in PC, while in FS-IN its application does not induce any changes. 
However, in FS-IN we observed little or no tail current to begin with. The use of a selective 
inhibitor of the KCNQ channels did not generate on its own gamma oscillations, but the 
application of a KCNQ channel opener counteracted the generation of gamma oscillations 
induced by histamine. Therefore, it seems that KCNQ channels inhibition is necessary but not 
sufficient for histamine-induced gamma oscillations.  
As said previously, the generation of gamma oscillations depends both on the excitability of 
pyramidal cells and FS-IN and on efficient synaptic signaling. We therefore studied EPSCs 
and IPSCs in pyramidal cells. We did not see any changes in the excitatory synaptic currents’ 
parameters in presence of histamine. As for IPSCs, no changes in the total charge transfer 
were detected but the analysis of their spectral power in the gamma-band revealed a 
significant increase in presence of histamine.  
We next examined the phase-preference of action potential firing of PC and FS-IN during 
histamine-induced gamma oscillations. By comparing the phase angle of PC to that of FS-IN 
we could establish that pyramidal cells fire significantly earlier than fast spiking interneurons 
in each cycle, consistently with what has been previously described (Fisahn et al., 1998; 
Tukker et al., 2007; Buzsáki and Wang, 2012). 
In summary, in this study we describe a new physiological mechanism to generate gamma 
oscillations in the hippocampus that seems to be dependent on the inhibition of KCNQ 
channels.  
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4.4 Paper IV 
While in paper III the focus was on H1 receptor, in this study H3 receptors are investigated 
as potential target for the treatment of circadian rhythm and cognitive dysfunction in a mouse 
model of Parkinson’s disease.  
As mentioned in the introduction, the non-motor symptoms of PD are getting increasingly 
more attention for being a main issue in the disease. At the same time, the role of histamine in 
the basal ganglia physiology and in the pathophysiology of PD is an emerging question. Post-
mortem studies have revealed altered levels of histamine in different neurological and 
psychiatric disorders, and specifically abnormally high concentrations in PD patients (Rinne 
et al., 2002); histaminergic neurons are also known to regulate wakefulness through their 
pacemaker-like firing pattern in the tuberomamillary nucleus (Taddese and Bean 2002). Of 
importance, especially for sleep related symptoms of Parkinson’s disease, is the H3 receptor. 
It was originally described in 1983 as a presynaptic autoreceptor, responsible for the 
inhibition of histamine release in the brain (Arrang et al., 1983) and, later on, it was shown to 
have a role as a heteroreceptor as well (Blandina et al., 1996; Schlicker et al., 1998). 
Antagonizing pharmacologically the H3 receptor has been proven effective in counteracting 
narcolepsy (Lin et al., 2008; Guo et al., 2009; Lin et al., 2011). 
In this paper we compare mice in which depletion of DA neurons was induced by injecting 6-
OHDA in each striatum and control mice that received a sham bilateral lesion. To study the 
effects of the lesion, mice were first monitored during 12h:12h light/dark cycle, and we 
observed that 6-OHDA-lesion mice exhibited reduced spontaneous motor activity during the 
dark phase (active phase) of the 24-hour cycle compared to control mice. Moreover, the 
following maintenance of these mice in constant darkness for 21 days showed a disruption in 
the endogenous circadian rhythm: 6-OHDA-lesion mice showed undefined rest/activity 
periods and overall lowered activity levels, in contrast with sham mice who maintained their 
normal activity pattern during day and night. We then tested the effects of thioperamide, a 
selective H3 antagonist (Arrang et al., 1987), on the disrupted circadian rhythm in 6-OHDA 
and sham mice in a 12h:12h light/dark cycle (see timeline on paper). The administration of 
thioperamide restored the normal rest/activity distribution in 6-OHDA-lesion mice.  
To evaluate the effects of thioperamide on cognitive impairment induced by 6-OHDA-lesion, 
we studied 1) the novel object recognition test performance of treated mice; 2) in vitro 
gamma oscillations power changes on hippocampal slices from injected and treated animals. 
Animals with 6-OHDA-lesion were confirmed to be unable to recognize novel objects after a 
familiarization phase, as proven previously (Bonito-Oliva et al., 2014). This deficit was, 
however, reversed with the administration of thioperamide.  
Gamma oscillations have been shown to be degraded in non-demented PD patients, 
underlying their cognitive decline (Olde Dubbelink et al., 2013). Sham- and 6-OHDA-lesion 
mice were sacrificed and hippocampal slices were obtained (see paper). Gamma oscillations 
were induced with KA and LFP were recorded in area CA3 of the hippocampus. Stable 
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oscillations recorded from sham mice injected with saline were indistinguishable from 
gamma oscillations recorded from naïve mice, while gamma oscillations recorded from 6-
OHDA-lesion mice were severely disrupted. In slices obtained from 6-OHDA-lesion mice 
injected with thioperamide, however, the power of gamma oscillations recorded was restored 
to control levels. The reduction of gamma oscillations in 6-OHDA-lesion mice indicates that 
dopaminergic innervation of the hippocampus is compromised, and could explain the 
impairment of long-term novel object recognition. It has been reported that the activation of 
H3 reduced the power of gamma oscillations induced by KA on WT hippocampal slices 
(Andersson et al., 2010). However, how thioperamide rescues the power is still to be 
elucidated. The H3 receptor mediates presynaptic inhibition of several neurotransmitters 
release, including dopamine (Schlicker et al., 1994; Hill et al., 1997; Brown et al., 2001). Its 
inhibition, therefore, might remove the inhibition on D1, thus facilitating the dopamine 
transmission. The inhibition of H3 receptors with the antagonist GSK189254 was reported to 
increase acetylcholine, dopamine and noradrenaline levels in the anterior cingulate cortex and 
acetylcholine in the hippocampus, and was suggested to improve cognitive performance in 
AD (Medhurst et al., 2007). Interestingly, in a recently published study, non-motor symptoms 
(circadian rhythm and cognitive performance) in a mouse model of Huntington’s disease 
(where dopaminergic pathways are also compromised) were ameliorated with the antagonist 
GSK189254 (Whittaker et al., 2017).  
In summary, this study highlights the importance of H3 receptor antagonists as potential 
treatments for cognitive impairment and circadian rhythm dysregulation associated with PD.   
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5 CONCLUSIONS 
 
The intriguing ability of the brain to generate electrical oscillations through the synchronized 
activity of neurons is extremely relevant in both physiology and pathology of the brain. Brain 
rhythms are very well conserved across different species (Buzsáki et al., 2013). In particular, 
frequency bands and temporal aspects of human oscillations (with their respective behavioral 
correlates) can be found in many other mammals (Buzsáki et al., 2013), making them 
important for translational research. The study of non-invasive EEG recordings can be linked 
to pre-clinical research. This is of particular relevance in pathologies, where the alteration of 
brain rhythms in patients can be studied in detail in research animals in vitro and can 
potentially lead to the identification of the pathophysiological mechanisms responsible for the 
alterations. In vitro preparations are ideal for pharmacological manipulation and give direct 
visual controls of the area or cells of interest for the recordings (Teyler, 1980). However, 
even though many conditions can be controlled during electrical recordings in brain slices, 
the slicing process itself damages the tissue, removing it from the blood supply and truncating 
many inputs coming from distant brain regions. Moreover, even though the disease models 
used in this thesis are well validated and broadly used, they do not reproduce all aspects of 
the diseases in question. Further in vivo experiments are necessary to continue these studies 
starting from behavioral experiments in animal models (already initiated in the case of 
papers II and IV, in preparation for paper I). Moreover, for all the studies described here 
more detailed experiments on the role of other cell types important for cognition (various 
interneuron sub-types, astrocytes, microglia) will need to be performed. 
The various compounds used in these projects to prevent or rescue neuronal damage have 
possible clinical applications. For AD, the two different approaches use FDA-approved drugs 
(in the case of T-type calcium channel inhibitors) or insulin and pyruvate, compounds known 
to be not harmful if potentially used in patients. Moreover, they are all known to cross the 
blood-brain barrier. The use of these compounds in in vitro models gave promising results in 
counteracting the effects of Aβ at different system levels. The two approaches act on 
mechanisms that are common to other neurodegenerative diseases as well, including PD 
(Yang et al., 2014; Anandhan et al., 2017; Athauda and Foltynie, 2016) and potentially 
Huntington’s disease (HD) (Giacomello et al., 2013; Lalić et al., 2008). Similar studies to 
those presented in this thesis are already planned in our lab in PD and HD mouse models as 
well as on iPS cells from PD and HD patients.  
On the other hand, the presented study on PD investigates the role of histamine in cognition-
relevant network rhythms and at a behavioral level in mice. The neuronal histaminergic 
system is involved in many physiological functions (potentially also in the in vivo generation 
of gamma oscillations, as examined in paper III) and is known to be disrupted in many 
neurodegenerative disorders. The modulation of histamine levels or modulation of histamine 
receptors might be useful in the fight against AD and PD. 
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In conclusion, the studies included in this thesis provide new insight into mechanisms 
potentially involved in in vivo gamma oscillations generation and mechanisms behind the 
disruption of gamma oscillations (and their linked cognitive deficiencies) in 
neurodegenerative diseases and suggest potential treatment strategies to prevent and rescue 
these deficiencies.  
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